Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.

Anti-cancer Drugs
Xiaotan LinTingting Chen

Abstract

Colorectal cancer (CRC) is the third most common malignancy worldwide. Our previous studies have shown that combinatorial treatment with thioridazine and loratadine may effectively inhibit CRC. However, the translation of these research findings to clinical practice was impaired by issues related to a lack of therapeutic specificity and to immune evasion. Toll-like receptor (TLR) agonists have been used as adjuvants to enhance the effectiveness of cancer vaccines. The aim of this study was to evaluate the therapeutic efficiency of immunotherapy with thioridazine and loratadine in combination with resiqumiod (R848), a small-molecule TLR7 agonist, in suppressing CRC growth in a mouse model. Twenty-four BALB/c mice were randomly assigned to treatment with PBS, R848, thioridazine + loratadine, or thioridazine + loratadine + R848. Cytokine levels were measured with ELISA. Overall survival, as well as tumor volume and tumor weight, was recorded. Cytotoxicity was measured by counting the numbers of CD8 and CD3-positive (CD8CD3) or CD4 and CD3-positive (CD3CD4) T-cells. The immune response induced by cytokines (as interferon-γ, interleukin-6, and tumor necrosis factor-α) was significantly stronger in mice treated with thioridazine + lo...Continue Reading

References

Dec 23, 1999·Clinical Immunology : the Official Journal of the Clinical Immunology Society·R P BurnsA A Gaspari
Nov 10, 2000·International Journal of Clinical Pharmacology and Therapeutics·I SoriaM Owens
Aug 17, 2011·Frontiers in Physiology·Balachandran ManavalanSangdun Choi
Jul 4, 2012·Current Opinion in Pharmacology·Dympna J Connolly, Luke A J O'Neill
Mar 12, 2013·Journal of Leukocyte Biology·Sabina KaczanowskaEduardo Davila
Nov 19, 2013·Immunity·Vincenzo Bronte, Mikael J Pittet
Dec 17, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gregory L Beatty, Whitney L Gladney
Jan 15, 2015·Cancer Cell·Nicholas McGranahan, Charles Swanton
Nov 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Luis Martínez-LostaoJulián Pardo
Nov 19, 2015·Journal of Leukocyte Biology·Ann J LigockiJerry Y Niederkorn
Feb 13, 2016·Biochimica Et Biophysica Acta·Fernando MendesManuel Santos Rosa
Mar 19, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Quan RaoHaiFang Yin
May 14, 2016·Nature Reviews. Rheumatology·Leo A B JoostenMihai G Netea
Nov 3, 2016·Nature Reviews. Clinical Oncology·Malte MohmeKlaus Pantel
Dec 22, 2016·Immunology and Cell Biology·Kyohei Nakamura, Mark J Smyth
Feb 19, 2017·Cold Spring Harbor Perspectives in Medicine·Eishu Hirata, Erik Sahai
Nov 1, 2017·Oncology Letters·Tingting ChenGuangyi Jin
Dec 7, 2018·Journal of Cellular Physiology·Bagher FarhoodKeywan Mortezaee
Jan 9, 2019·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Apr 14, 2019·Cancers·Ben WylieJason Waithman
Oct 17, 2019·Nature Communications·Katherine A MichaelisDaniel L Marks

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Diseases of the Nervous System
H Z WINNIKB TOMIN
The American Journal of Emergency Medicine
Y GokelA Sebe
© 2021 Meta ULC. All rights reserved